Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.
Daniel CaldeiraFilipe B RodriguesMarta M DuarteCarmelo SterrantinoMárcio BarraNilza GonçalvesFausto J PintoJoaquim J FerreiraJoão CostaPublished in: Drug safety (2018)
The pooled data from RCTs did not show an increased risk of cardiac outcomes, including arrhythmias (and bradycardia), among sofosbuvir-treated patients, although the overall quality of the evidence supporting this conclusion was very low. Registration: PROSPERO 2016:CRD42016033109 at http://www.crd.york.ac.uk/PROSPERO/ .
Keyphrases
- hepatitis c virus
- end stage renal disease
- newly diagnosed
- left ventricular
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- clinical trial
- prognostic factors
- hepatitis c virus infection
- heart failure
- electronic health record
- machine learning
- big data
- quality improvement
- skeletal muscle
- patient reported outcomes
- patient reported
- open label
- congenital heart disease
- weight loss
- deep learning
- artificial intelligence
- atrial fibrillation
- study protocol